Diclofenac enhances allergic responses in a mouse peanut allergy model

Clinical and Experimental Allergy

Volumn 41, Issue 3, 2011, Pages 424-433

  Bol Schoenmakers, M ^a   Bleumink, R ^a   Marcondes Rezende, M ^a,b   Mouser, E ^a   Hassing, I ^a   Ludwig, I ^a,c   Smit, J J ^a,b   Pieters, R H H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b Utrecht Center for Food Allergy   (Netherlands)

^c TI Pharma   (Netherlands)

Author keywords

Cyclo oxygenase; Diclofenac; Mouse allergy model; Non steriodal anti inflammatory drugs; Oral tolerance; Peanut allergy

Indexed keywords

CHOLERA TOXIN; DICLOFENAC; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY;

ALLERGIC REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; FEMALE; IMMUNOLOGICAL TOLERANCE; INTESTINE INJURY; MOUSE; NONHUMAN; PEANUT ALLERGY; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DISEASE MODELS, ANIMAL; FEMALE; IMMUNE TOLERANCE; MICE; PEANUT HYPERSENSITIVITY;

EID: 79551637153     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2010.03594.x     Document Type: Article

References (35)

1. Ganeshan K, Neilsen CV, Hadsaitong A, Schleimer RP, Luo X, Bryce PJ. Impairing oral tolerance promotes allergy and anaphylaxis: a new murine food allergy model. J Allergy Clin Immunol 2009; 123:231-8.
2. Berin MC, Mayer L. Immunophysiology of experimental food allergy. Mucosal Immunol 2009; 2:24-32.
3. Berin MC, Shreffler WG T(H)2 adjuvants: implications for food allergy. J Allergy Clin Immunol 2008; 121:1311-20; quiz 1321-1322.
4. Shirai T, Matsui T, Uto T, Chida K, Nakamura H. Nonsteroidal anti-inflammatory drugs enhance allergic reactions in a patient with wheat-induced anaphylaxis. Allergy 2003; 58:1071.
5. Pecquet S, Prioult G, Campbell J, German B, Turini M. Commonly used drugs impair oral tolerance in mice. Ann N Y Acad Sci 2004; 1029:374-8.
6. Broere F, du Pre MF, van Berkel LA et al. Cyclooxygenase-2 in mucosal DC mediates induction of regulatory T cells in the intestine through suppression of IL-4. Mucosal Immunol 2009; 2:254-6.
7. Nierkens S, Aalbers M, Bol M, van Wijk F, Hassing I, Pieters R. Development of an oral exposure mouse model to predict drug-induced hypersensitivity reactions by using reporter antigens. Toxicol Sci 2005; 83:273-81.
8. Harizi H, Gualde N. The impact of eicosanoids on the crosstalk between innate and adaptive immunity: the key roles of dendritic cells. Tissue Antigens 2005; 65:507-14.
9. Serhan CN, Chiang N, Van Dyke TE. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 2008; 8:349-61.
10. Hilario MO, Terreri MT, Len CA. Nonsteroidal anti-inflammatory drugs: cyclooxygenase 2 inhibitors. J Pediatr (Rio J) 2006; 82:S206-212.
11. Rocca B, FitzGerald GA. Cyclooxygenases and prostaglandins: shaping up the immune response. Int Immunopharmacol 2002; 2:603-30.
12. Baratelli F, Lin Y, Zhu L et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+T cells. J Immunol 2005; 175:1483-90.
13. Newberry RD, McDonough JS, Stenson WF, Lorenz RG. Spontaneous and continuous cyclooxygenase-2-dependent prostaglandin E2 production by stromal cells in the murine small intestine lamina propria: directing the tone of the intestinal immune response. J Immunol 2001; 166:4465-72.
14. Morteau O. COX-2: promoting tolerance. Nat Med 1999; 5:867-8.
15. Stenson WF. Prostaglandins and epithelial response to injury. Curr Opin Gastroenterol 2007; 23:107-10.
16. Fukata M, Chen A, Klepper A et al. Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 2006; 131:862-77.
17. van Wijk F, Hoeks S, Nierkens S et al. CTLA-4 signaling regulates the intensity of hypersensitivity responses to food antigens, but is not decisive in the induction of sensitization. J Immunol 2005; 174:174-9.
18. Bens M, Bogdanova A, Cluzeaud F et al. Transimmortalized mouse intestinal cells (m-ICc12) that maintain a crypt phenotype. Am J Physiol 1996; 270:C1666-1674.
19. Hornef MW, Normark BH, Vandewalle A, Normark S. Intracellular recognition of lipopolysaccharide by toll-like receptor 4 in intestinal epithelial cells. J Exp Med 2003; 198:1225-3.
20. Knowles SR, Drucker AM, Weber EA, Shear NH. Management options for patients with aspirin and nonsteroidal antiinflammatory drug sensitivity. Ann Pharmacother 2007; 41:1191-200.
21. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib. Ann Allergy Asthma Immunol 2005; 94:34-8.
22. Harada S, Horikawa T, Ashida M, Kamo T, Nishioka E, Ichihashi M. Aspirin enhances the induction of type I allergic symptoms when combined with food and exercise in patients with food-dependent exercise-induced anaphylaxis. Br J Dermatol 2001; 145:336-9.
23. Vidal C, Bartolome B, Gonzalez-Quintela A, Rodriguez V, Armisen M. Prawns, barnacles, and nonsteroidal anti-inflammatory drugs: effect modifiers or diagnostic confounders [corrected]. J Invest Allergol Clin Immunol 2007; 17:113-8.
24. Blumberg RS, Pitman RS, Taylor CT, Colgan SP. Cholera toxin potentiates influences of IFN-gamma through activation of NF-kappaB and release of tumor necrosis factor-alpha. J Interferon Cytokine Res 2005; 25:209-1.
25. Blazquez AB, Berin MC. Gastrointestinal dendritic cells promote Th2 skewing via OX40L. J Immunol 2008; 180:4441-50.
26. Yang PC, Xing Z, Berin CM et al. TIM-4 expressed by mucosal dendritic cells plays a critical role in food antigen-specific Th2 differentiation and intestinal allergy. Gastroenterology 2007; 133:1522-33.
27. Anosova NG, Chabot S, Shreedhar V, Borawski JA, Dickinson BL, Neutra MR, Cholera toxin E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches. Mucosal Immunol 2008; 1:59-67.
28. Grosman N. Comparison of the influence of NSAIDs with different COX-selectivity on histamine release from mast cells isolated from naive and sensitized rats. Int Immunopharmacol 2007; 7:532-40.
29. Bjarnason I, Takeuchi K. Intestinal permeability in the pathogenesis of NSAID-induced enteropathy. J Gastroenterol 2009; 44 (Suppl 19):23-9.
30. Menozzi A, Pozzoli C, Giovannini E et al. Intestinal effects of nonselective and selective cyclooxygenase inhibitors in the rat. Eur J Pharmacol 2006; 552:143-50.
31. Yuan CJ, Mandal AK, Zhang Z, Mukherjee AB. Transcriptional regulation of cyclooxygenase-2 gene expression: novel effects of nonsteroidal anti-inflammatory drugs. Cancer Res 2000; 60:1084-91.
32. Lichtenberger LM, Zhou Y, Dial EJ, Raphael RM. NSAID injury to the gastrointestinal tract: evidence that NSAIDs interact with phospholipids to weaken the hydrophobic surface barrier and induce the formation of unstable pores in membranes. J Pharm Pharmacol 2006; 58:1421-8.
33. Riemer AB, Gruber S, Pali-Scholl I, Kinaciyan T, Untersmayr E, Jensen-Jarolim E. Suppression of gastric acid increases the risk of developing immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model. Clin Exp Allergy 40:486-93.
34. Matsuo H, Kaneko S, Tsujino Y et al. Effects of non-steroidal anti-inflammatory drugs (NSAIDs) on serum allergen levels after wheat ingestion. J Dermatol Sci 2009; 53:241-3.
35. Mazumdar K, Dastidar SG, Park JH, Dutta NK. The anti-inflammatory non-antibiotic helper compound diclofenac: an antibacterial drug target. Eur J Clin Microbiol Infect Dis 2009; 28:881-9.